Skip to main content

NO-GO: UNVEILING THE POWER OF C-08 FOR THE TREATMENT OF OVER ACTIVE BLADDER

Project description

Clinical validation of natural product for the treatment of overactive bladder symptoms

Overactive bladder (OAB) syndrome, with urinary symptoms of urgency and nocturia, affects 500 million people worldwide, with prevalence increase with age (>30 % over 75 years old). Icelandic SagaNatura has developed NO-GO, a natural product from the leaves of Angelica archangelica for improving OAB symptoms as a non-prescription urinary product. Its efficiency and safety were recently clinically validated in a small-scale clinical trial on 66 patients with OAB. The current EU-funded NO-GO phase2 project aims to fine-tune the formulation, increase the production capacity and extend the clinical validation. The objective is to prepare the product for expansion in Europe and North American markets.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Coordinator

SAGANATURA EHF
Net EU contribution
€ 1 562 729,00
Address
Sudurhellu 8
221 Hafnarfjordur
Iceland

See on map

Region
Ísland Ísland Höfuðborgarsvæði
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 669 741,00